p-cresyl sulfate and indoxyl sulfate in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 12, 2009, Pages 1932-1938

  Meijers, Björn K I ^a   De Loor, Henriette ^a   Bammens, Bert ^a   Verbeke, Kristin ^a   Vanrenterghem, Yves ^a   Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; INDICAN; PARA CRESOL;

ADULT; AGED; ARTICLE; BINDING COMPETITION; BINDING SITE; CLEARANCE; COHORT ANALYSIS; FEMALE; HEMODIALYSIS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METABOLISM; OBSERVATIONAL STUDY; PATIENT MONITORING; PROTEIN BINDING; PROTEIN BLOOD LEVEL; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; CRESOLS; FEMALE; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL DIALYSIS; SERUM ALBUMIN; SULFURIC ACID ESTERS; UREA;

EID: 73649142365     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02940509     Document Type: Article

References (31)

1. Meyer TW, Hostetter TH: Uremia. N Engl J Med 357: 1316-1325, 2007
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu Cy: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305. 2004
3. Depner T, Himmelfarb J: Uremic retention solutes: The free and the bound. J Am Soc Nephrol 18: 675-676, 2007
4. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47: 565-577, 2006
5. Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, Walther JL, Hostetter TH: Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol 18: 868-874, 2007
6. Meijers BKI, Weber V, Bammens B, Dehaen W, Verbeke K, Falkenhagen D, Evenepoel P: Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 32: 214-219, 2008
7. Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer TW: Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: A pilot crossover trial. Am J Kidney Dis 43: 1042-1049, 2009
8. Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 16: 3430-3436, 2005
9. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. Am J Kidney Dis 44: 278-285, 2004
10. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of [beta]2-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 70: 794-799, 2006
11. Miyazaki T, Ise M, Hirata M, Endo K, Ito Y, Seo H, Niwa T: Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int 52: S211-S214, 1997
12. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 52: S23-S28, 1997
13. Niwa T: Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 3: 167-182, 1996
14. Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T: Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 23: 1892-1901, 2008
15. Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, Yamato H, Kurokawa K, Fukagawa M: Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71: 738-743, 2007
16. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the proteinbound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 69: 1081-1087, 2006
17. Meijers BKI, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P: Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1173-1180, 2008
18. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009, in press
19. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22: 592-596, 2007
20. Stanfel LA, Gulyassy PF, Jarrard EA: Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography. Clin Chem 32: 938-942, 1986
21. Niwa T, Takeda N, Tatematsu A, Maeda K: Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34: 2264-2267, 1988
22. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K: Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 51: 1535-1538, 2005
23. Sudlow G, Birkett D, Wade D: The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11: 824-832, 1975
24. Meijers BKI, Bammens B, Verbeke K, Evenepoel P: A review of albumin binding in CKD. Am J Kidney Dis 51: 839-850, 2008
25. Meyer TW, Leeper EC, Bartlett DW, Depner TA, Lit YZ, Robertson CR, Hostetter TH: Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 15: 1927-1935, 2004
26. de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, Evenepoel P: Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 1216: 4684-4688, 2009
27. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74: 349-355, 1996
28. Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P: p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2009, in press
29. Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A, Otagiri M: Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res 18: 520-524, 2001
30. Sakai T, Takadate A, Otagiri M: Characterisation of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 18: 1755-1761, 1995
31. Breyer B, Radcliff F: The adsorptive capacity of serum proteins in renal insufficiency. Austral J Exp Biol 32: 411-420, 1954